α4β1-Integrin Does Not Support Rolling of DHCB-Treated Neutrophils on TNFα-Stimulated Endothelium
| Neutrophil Treatment . | Rolling Cells (no./mm2 ) . |
|---|---|
| DHCB + IB4 | 84.5 ± 12.3 |
| DHCB + IB4 + HP2/1 (anti-α4) | 149.9 ± 22.7* |
| DHCB + IB4 + HP1/2 (anti-α4) | 114.5 ± 2.5* |
| DHCB + IB4 + K20 (anti-β1) | 122.7 ± 4.5* |
| DHCB + IB4 + LIA1/2 (anti-β1) | 150.8 ± 55.7* |
| DHCB + IB4 + isotype control | 73.1 ± 15.6 |
| DHCB + HP2/1 | 96.2 ± 9.2 |
| Neutrophil Treatment . | Rolling Cells (no./mm2 ) . |
|---|---|
| DHCB + IB4 | 84.5 ± 12.3 |
| DHCB + IB4 + HP2/1 (anti-α4) | 149.9 ± 22.7* |
| DHCB + IB4 + HP1/2 (anti-α4) | 114.5 ± 2.5* |
| DHCB + IB4 + K20 (anti-β1) | 122.7 ± 4.5* |
| DHCB + IB4 + LIA1/2 (anti-β1) | 150.8 ± 55.7* |
| DHCB + IB4 + isotype control | 73.1 ± 15.6 |
| DHCB + HP2/1 | 96.2 ± 9.2 |
In each case, the addition of anti-α4 (HP2/1 or HP1/2) or anti-β1 (K20 or LIA1/2) antibodies in the presence of IB4 blocked the adhesion, which translated into increased rolling (5-minute values).
P < .05 relative to DHCB + IB4 condition.